{
    "root": "8057fdd1-5622-47a8-a84d-ae31cc1eca6d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Arcalyst",
    "value": "20250307",
    "ingredients": [
        {
            "name": "RILONACEPT",
            "code": "8K80YB5GMG"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C"
        }
    ],
    "indications": "arcalyst ( rilonacept ) interleukin-1 blocker indicated : treatment cryopyrin-associated periodic syndromes ( caps ) , including familial cold autoinflammatory syndrome ( fcas ) , muckle-wells syndrome ( mws ) adults children 12 years older ( 1.1 , 14.1 ) maintenance remission deficiency interleukin-1 receptor antagonist ( dira ) adults pediatric patients weighing 10 kg ( 1.2 , 14.2 ) treatment recurrent pericarditis ( rp ) reduction risk recurrence adults children 12 years older ( 1.3 , 14.3 )",
    "contraindications": "administer subcutaneous injection ( 2.1 ) caps , fcas , mws , rp ( 2.2 ) : adults : – loading dose : 320 mg , delivered two 160 mg ( 2 ml ) injections . – maintenance dose : 160 mg ( 2 ml ) injection weekly . pediatric patients 12 years 17 years : – loading dose : 4.4 mg/kg , maximum 320 mg , delivered 1 2 injections ( exceed 2 ml/injection ) . – maintenance dose : 2.2 mg/kg , maximum 160 mg ( 2 ml ) injection , weekly . dira ( 2.3 ) : adults pediatric patients weighing 10 kg : – 4.4 mg/kg maximum 320 mg , delivered 1 2 injections ( 2 ml/injection ) weekly .",
    "warningsAndPrecautions": "arcalyst ( rilonacept ) injection supplied sterile , white off-white , preservative-free , lyophilized powder single-dose vials . 220 mg vial arcalyst supplied carton containing one vial ( ndc 73604-914-01 ) four vials ( ndc 73604-914-04 ) .",
    "adverseReactions": "none .",
    "indications_original": "ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 )",
    "contraindications_original": "Administer by subcutaneous injection ( 2.1 ) CAPS, FCAS, MWS, and RP ( 2.2 ): Adults: – Loading dose: 320 mg, delivered as two 160 mg (2 mL) injections. – Maintenance dose:  160 mg (2 mL) injection once weekly. Pediatric patients 12 years to 17 years: – Loading dose: 4.4 mg/kg, up to a maximum of 320 mg, delivered as 1 or 2 injections (not to exceed 2 mL/injection). – Maintenance dose: 2.2 mg/kg, up to a maximum of 160 mg (2 mL) injection, once weekly. DIRA ( 2.3 ): Adults and pediatric patients weighing 10 kg or more: – 4.4 mg/kg up to a maximum of 320 mg, delivered as 1 or 2 injections (2 mL/injection) once weekly.",
    "warningsAndPrecautions_original": "ARCALYST (rilonacept) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder in single-dose vials.\n                  Each 220 mg vial of ARCALYST is supplied in a carton containing one vial (NDC 73604-914-01) or four vials (NDC 73604-914-04).",
    "adverseReactions_original": "None."
}